vs
Side-by-side financial comparison of Cytek Biosciences, Inc. (CTKB) and TSS, Inc. (TSSI). Click either name above to swap in a different company.
Cytek Biosciences, Inc. is the larger business by last-quarter revenue ($62.1M vs $60.9M, roughly 1.0× TSS, Inc.). TSS, Inc. runs the higher net margin — 20.0% vs -70.9%, a 90.9% gap on every dollar of revenue. On growth, TSS, Inc. posted the faster year-over-year revenue change (21.8% vs 8.1%). TSS, Inc. produced more free cash flow last quarter ($15.8M vs $-1.8M). Over the past eight quarters, TSS, Inc.'s revenue compounded faster (95.8% CAGR vs 17.7%).
Cytek Biosciences, Inc. develops, manufactures and sells high-performance flow cytometry systems, associated reagents and analysis software. Its solutions serve life science research, clinical diagnostics and biopharmaceutical sectors, with a global customer base across North America, Europe and the Asia-Pacific region.
CTKB vs TSSI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $62.1M | $60.9M |
| Net Profit | $-44.1M | $12.2M |
| Gross Margin | 52.9% | 17.6% |
| Operating Margin | -9.0% | 1.5% |
| Net Margin | -70.9% | 20.0% |
| Revenue YoY | 8.1% | 21.8% |
| Net Profit YoY | -557.1% | 535.7% |
| EPS (diluted) | — | $0.44 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $62.1M | $60.9M | ||
| Q3 25 | $52.3M | $41.9M | ||
| Q2 25 | $45.6M | $44.0M | ||
| Q1 25 | $41.5M | $99.0M | ||
| Q4 24 | $57.5M | $50.0M | ||
| Q3 24 | $51.5M | $70.1M | ||
| Q2 24 | $46.6M | $12.2M | ||
| Q1 24 | $44.9M | $15.9M |
| Q4 25 | $-44.1M | $12.2M | ||
| Q3 25 | $-5.5M | $-1.5M | ||
| Q2 25 | $-5.6M | $1.5M | ||
| Q1 25 | $-11.4M | $3.0M | ||
| Q4 24 | $9.6M | $1.9M | ||
| Q3 24 | $941.0K | $2.6M | ||
| Q2 24 | $-10.4M | $1.4M | ||
| Q1 24 | $-6.2M | $15.0K |
| Q4 25 | 52.9% | 17.6% | ||
| Q3 25 | 52.7% | 11.1% | ||
| Q2 25 | 52.3% | 17.8% | ||
| Q1 25 | 48.6% | 9.3% | ||
| Q4 24 | 58.5% | 14.4% | ||
| Q3 24 | 56.3% | 11.3% | ||
| Q2 24 | 54.6% | 37.3% | ||
| Q1 24 | 51.3% | 17.1% |
| Q4 25 | -9.0% | 1.5% | ||
| Q3 25 | -17.6% | -2.2% | ||
| Q2 25 | -23.3% | 5.1% | ||
| Q1 25 | -36.1% | 4.2% | ||
| Q4 24 | 5.2% | 0.0% | ||
| Q3 24 | -8.2% | 5.4% | ||
| Q2 24 | -18.3% | 14.0% | ||
| Q1 24 | -23.9% | 1.6% |
| Q4 25 | -70.9% | 20.0% | ||
| Q3 25 | -10.5% | -3.6% | ||
| Q2 25 | -12.2% | 3.4% | ||
| Q1 25 | -27.5% | 3.0% | ||
| Q4 24 | 16.8% | 3.8% | ||
| Q3 24 | 1.8% | 3.8% | ||
| Q2 24 | -22.4% | 11.5% | ||
| Q1 24 | -13.8% | 0.1% |
| Q4 25 | — | $0.44 | ||
| Q3 25 | — | $-0.06 | ||
| Q2 25 | — | $0.06 | ||
| Q1 25 | — | $0.12 | ||
| Q4 24 | — | $0.08 | ||
| Q3 24 | — | $0.10 | ||
| Q2 24 | — | $0.06 | ||
| Q1 24 | — | $0.00 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $90.9M | $85.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $341.7M | $76.6M |
| Total Assets | $461.5M | $184.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $90.9M | $85.5M | ||
| Q3 25 | $93.3M | $70.7M | ||
| Q2 25 | $75.5M | — | ||
| Q1 25 | $95.3M | — | ||
| Q4 24 | $98.7M | $23.2M | ||
| Q3 24 | $162.3M | $46.4M | ||
| Q2 24 | $177.9M | $8.3M | ||
| Q1 24 | $168.8M | $14.4M |
| Q4 25 | $341.7M | $76.6M | ||
| Q3 25 | $378.6M | $63.4M | ||
| Q2 25 | $377.6M | $9.5M | ||
| Q1 25 | $379.6M | $9.4M | ||
| Q4 24 | $395.7M | $7.1M | ||
| Q3 24 | $385.5M | $7.7M | ||
| Q2 24 | $389.1M | $5.2M | ||
| Q1 24 | $392.6M | $3.7M |
| Q4 25 | $461.5M | $184.9M | ||
| Q3 25 | $494.9M | $165.4M | ||
| Q2 25 | $493.3M | $139.5M | ||
| Q1 25 | $482.6M | $113.5M | ||
| Q4 24 | $499.5M | $96.6M | ||
| Q3 24 | $491.2M | $67.3M | ||
| Q2 24 | $483.7M | $28.9M | ||
| Q1 24 | $492.1M | $26.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-771.0K | $16.3M |
| Free Cash FlowOCF − Capex | $-1.8M | $15.8M |
| FCF MarginFCF / Revenue | -2.9% | 25.9% |
| Capex IntensityCapex / Revenue | 1.6% | 0.9% |
| Cash ConversionOCF / Net Profit | — | 1.34× |
| TTM Free Cash FlowTrailing 4 quarters | $-8.8M | $2.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-771.0K | $16.3M | ||
| Q3 25 | $-3.9M | $-18.4M | ||
| Q2 25 | $108.0K | $16.3M | ||
| Q1 25 | $-125.0K | $20.6M | ||
| Q4 24 | $2.0M | $-21.6M | ||
| Q3 24 | $13.2M | $38.6M | ||
| Q2 24 | $6.2M | $-4.3M | ||
| Q1 24 | $4.0M | $2.6M |
| Q4 25 | $-1.8M | $15.8M | ||
| Q3 25 | $-4.6M | $-24.9M | ||
| Q2 25 | $-1.5M | $5.4M | ||
| Q1 25 | $-974.0K | $5.8M | ||
| Q4 24 | $1.1M | $-28.4M | ||
| Q3 24 | $12.2M | $38.6M | ||
| Q2 24 | $5.2M | $-6.0M | ||
| Q1 24 | $3.4M | $2.6M |
| Q4 25 | -2.9% | 25.9% | ||
| Q3 25 | -8.7% | -59.3% | ||
| Q2 25 | -3.2% | 12.3% | ||
| Q1 25 | -2.3% | 5.8% | ||
| Q4 24 | 1.9% | -56.7% | ||
| Q3 24 | 23.7% | 55.1% | ||
| Q2 24 | 11.0% | -49.4% | ||
| Q1 24 | 7.6% | 16.4% |
| Q4 25 | 1.6% | 0.9% | ||
| Q3 25 | 1.3% | 15.3% | ||
| Q2 25 | 3.5% | 24.8% | ||
| Q1 25 | 2.0% | 15.0% | ||
| Q4 24 | 1.6% | 13.4% | ||
| Q3 24 | 2.0% | 0.1% | ||
| Q2 24 | 2.3% | 13.8% | ||
| Q1 24 | 1.3% | 0.2% |
| Q4 25 | — | 1.34× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 11.02× | ||
| Q1 25 | — | 6.93× | ||
| Q4 24 | 0.21× | -11.32× | ||
| Q3 24 | 14.05× | 14.60× | ||
| Q2 24 | — | -3.09× | ||
| Q1 24 | — | 176.40× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTKB
| Products | $46.6M | 75% |
| Services | $15.5M | 25% |
TSSI
| Procurement Revenues Segment | $43.2M | 71% |
| System Integration Services Segment | $14.2M | 23% |
| Facilities Segment | $3.5M | 6% |
